Tag: emphysema treatment market forecast

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Emphysema Treatment Market Covering 2025–2034?

The emphysema treatment market has demonstrated consistent expansion in recent years. Projections indicate it will expand from $5.15 billion in 2024 to $5.4 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 5.0%. Historically, this growth has been driven by factors such as the profound impact of the smoking epidemic, significant advancements in medications, the proliferation of pulmonary rehabilitation programs, the development of enhanced diagnostic tools, and increased awareness and education initiatives.

The emphysema treatment market size is anticipated to experience robust expansion in the coming years. It is projected to grow to $7.28 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 7.7%. This expansion during the forecast period can be attributed to factors such as an aging population, personalized treatment approaches, broader access to therapies, a greater emphasis on symptom management, and collaborative healthcare models. Significant trends anticipated in this period include the exploration of gene therapies, increased patient education and empowerment, the integration of artificial intelligence (AI), enhanced accessibility to treatment, and advancements in long-acting medications.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10807&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Emphysema Treatment Industry?

The growing incidence of chronic obstructive pulmonary disease (COPD) is projected to stimulate the expansion of the emphysema treatment market in the future. COPD refers to a group of conditions, including emphysema and chronic bronchitis, that obstruct airflow and cause breathing difficulties. Emphysema therapies are crucial in mitigating the progression of COPD, as their focus is on alleviating symptoms, restoring lung function, and delaying the disease’s advancement. For instance, in June 2024, reports from the Australian Institute of Health and Welfare (AIHW), an Australia-based agency, estimated that in 2022, about 638,000 people, or 2.5% of the population in Australia, were affected by COPD. By 2023, COPD’s contribution to the overall disease burden had climbed to 3.6%, constituting 50% of the total burden associated with respiratory conditions. Furthermore, in 2022, COPD was the direct cause of 7,691 deaths, which equals 29.6 deaths per 100,000 people and represented 4.0% of all fatalities in the country. Thus, the escalating prevalence of chronic obstructive pulmonary disease (COPD) cases is a significant driver for the emphysema treatment market.

What Are The Major Segments Identified In The Emphysema Treatment Market?

The emphysema treatment market covered in this report is segmented –

1) By Treatment: Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments

2) By Distribution Channel: Online Providers, Drug Stores and Retail Pharmacies, Hospital Pharmacies

3) By End-User: Clinics, Surgical Centre, Other End-Users

Subsegments:

1) By Smoking Cessation: Nicotine Replacement Therapy (NRT), Prescription Medications, Behavioral Therapy Programs

2) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics

3) By Steroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Combination Inhalers

4) By Leukotriene Modifiers: Montelukast, Zafirlukast

5) By Supplemental Oxygen: Portable Oxygen Concentrators, Continuous Flow Oxygen Systems, Pulse Dose Oxygen Systems

6) By Antibiotics: Macrolides, Fluoroquinolones, Tetracyclines

7) By Gene Therapy: Gene Replacement Therapy, Antisense Oligonucleotides

8) By Surgery Transplant: Lung Volume Reduction Surgery (LVRS), Lung Transplantation

9) By Other Treatments: Pulmonary Rehabilitation Programs, Nutritional Support, Palliative Care

What Trends Are Redefining The Emphysema Treatment Market Dynamics?

Leading firms within the emphysema sector are creating less invasive methods for patients to secure a market advantage. These procedures denote medical or surgical approaches executed with minimal disturbance to the body’s natural anatomy. An illustration of this is the introduction of Zephyr Valve surgery by Adena Health System, a US healthcare provider, in January 2022. This minimally invasive operation presents an option beyond standard lung volume reduction surgery for individuals suffering from lung hyperinflation, frequently observed in emphysema and COPD. The pioneering technique entails inserting small, unidirectional Zephyr Valves into the lung airways using a bronchoscope. These valves enable the expulsion of trapped air, hinder further buildup, permit expansion of healthier lung regions, and consequently enhance respiration.

Which Leading Companies Dominate The Emphysema Treatment Market Share?

Major companies operating in the emphysema treatment market include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Boehringer Ingelheim GmbH, Mylan N.V., Pfizer Inc., Orion Oyj, Verona Pharma PLC, Pulmonx Corporation, Emphasys Medical Inc., Halozyme Therapeutics Inc., Mariposa Health Limited, Uptake Technologies Inc., Respinova Ltd, Gala Therapeutics Inc., Pulmatrix Inc., Broncus Medical Inc., Holaira Inc., PneumRx Inc., Spiration Inc., Aeris Therapeutics Inc., CSA Medical Inc., Olympus Corporation

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/emphysema-treatment-global-market-report

What Regional Growth Trends Are Shaping The Emphysema Treatment Market Outlook?

North America was the largest region in the emphysema treatment market in 2024. The regions covered in the emphysema treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Emphysema Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10807&type=smp

Browse Through More Reports Similar to the Global Emphysema Treatment Market 2025, By The Business Research Company

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Point Of Entry Water Treatment Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/point-of-entry-water-treatment-systems-global-market-report

Point Of Use Water Treatment Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/point-of-use-water-treatment-systems-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Emphysema Treatment Industry?

The size of the market for emphysema treatment has been progressively expanding in the past few years. It’s projected that this growth will progress from $5.15 billion in 2024 to $5.4 billion in 2025, representing a compound annual growth rate (CAGR) of 5.0%. The expansion during the historic period can be accredited to factors like the impact of the smoking epidemic, progress in medicinal treatments, the implementation of pulmonary rehabilitation programs, enhancement in diagnostic tools, as well as increased awareness and education.

A significant increase is expected to be noted in the size of the emphysema treatment market in the coming years. It is projected to expand to “$7.28 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. Several factors, such as the aging population, personalized treatment methods, improved access to treatments, emphasis on managing symptoms, and cooperative healthcare systems, contribute to this predicted growth. Key emerging patterns within the forecast period encompass the development of gene therapy, patient knowledge and empowerment, the introduction of artificial intelligence (AI), enhanced treatment accessibility, and development of long-acting drugs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10807&type=smp

What Forces Are Driving The Growth Of The Emphysema Treatment Industry?

The growing number of chronic obstructive pulmonary disease (COPD) cases is anticipated to boost the emphysema treatment market’s expansion in the future. COPD is a collection of ailments that impede airflow and cause breathing difficulties, which includes conditions like emphysema and chronic bronchitis. Treatments for emphysema are crucial in slowing down the progression of COPD because they concentrate on symptom management, lung function restoration, and disease advancement delay. For example, the Australian Institute of Health and Welfare (AIHW) revealed in June 2024 that around 638,000 individuals in Australia, or 2.5% of the country’s population, were living with COPD in 2022. By 2023, COPD had accounted for 3.6% of the total disease burden, making up 50% of the respiratory conditions-related burden. Further, in 2022, COPD was the root cause of 7,691 deaths, translating to 29.6 deaths per 100,000 people and comprising 4.0% of all the country’s deaths. Thus, the increasing prevalence of COPD cases serves as a driving force for the expansion of the emphysema treatment market.

The emphysema treatment market covered in this report is segmented –

1) By Treatment: Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments

2) By Distribution Channel: Online Providers, Drug Stores and Retail Pharmacies, Hospital Pharmacies

3) By End-User: Clinics, Surgical Centre, Other End-Users

Subsegments:

1) By Smoking Cessation: Nicotine Replacement Therapy (NRT), Prescription Medications, Behavioral Therapy Programs

2) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics

3) By Steroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Combination Inhalers

4) By Leukotriene Modifiers: Montelukast, Zafirlukast

5) By Supplemental Oxygen: Portable Oxygen Concentrators, Continuous Flow Oxygen Systems, Pulse Dose Oxygen Systems

6) By Antibiotics: Macrolides, Fluoroquinolones, Tetracyclines

7) By Gene Therapy: Gene Replacement Therapy, Antisense Oligonucleotides

8) By Surgery Transplant: Lung Volume Reduction Surgery (LVRS), Lung Transplantation

9) By Other Treatments: Pulmonary Rehabilitation Programs, Nutritional Support, Palliative Care

How Are Key Trends Driving Expansion In The Emphysema Treatment Industry?

Major businesses in the emphysema market are innovating minimally invasive techniques for patients suffering from emphysema as a way to gain a competitive advantage in the market. Minimally invasive procedures encompass medical actions or surgical operations that constrain the disruption to the body’s regular structures. For example, Adena Health System, a healthcare company from the United States, introduced the Zephyr Valve surgery in January 2022. This progressive procedure, designed as an alternative to the traditional lung volume reduction surgery, addresses the common issue of lung hyperinflation found in emphysema and COPD patients. This unique strategy involves inserting tiny Zephyr Valves into the air passages of the lungs using a bronchoscope. These valves play a critical role in expelling confined air, hindering future buildup, and facilitating the expansion of healthier areas of the lungs, thereby enhancing breathing.

Who Are The Primary Players Operating Across The Global Emphysema Treatment Market?

Major companies operating in the emphysema treatment market include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Boehringer Ingelheim GmbH, Mylan N.V., Pfizer Inc., Orion Oyj, Verona Pharma PLC, Pulmonx Corporation, Emphasys Medical Inc., Halozyme Therapeutics Inc., Mariposa Health Limited, Uptake Technologies Inc., Respinova Ltd, Gala Therapeutics Inc., Pulmatrix Inc., Broncus Medical Inc., Holaira Inc., PneumRx Inc., Spiration Inc., Aeris Therapeutics Inc., CSA Medical Inc., Olympus Corporation

https://www.thebusinessresearchcompany.com/report/emphysema-treatment-global-market-report

Which Region Offers The Most Growth Potential For The Emphysema Treatment Market Through 2029?

North America was the largest region in the emphysema treatment market in 2024. The regions covered in the emphysema treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10807&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Emphysema Treatment Market Evolve in Terms of Growth and Size by 2029?

In recent years, we have observed a consistent growth in the emphysema treatment market. The market size is projected to increase from $5.15 billion in 2024 to $5.4 billion in 2025, implying a compound annual growth rate (CAGR) of 5.0%. The expansion observed during the historic period was a result of the effect of the smoking epidemic, advancements in medicine, implementation of pulmonary rehabilitation programs, the development of better diagnostic tools, and increased awareness and education.

The market size for emphysema treatment is projected to experience robust expansion in the coming years, reaching $7.28 billion in 2029 with a CAGR of 7.7%. The expected growth during the forecast period can be attributed to factors such as the ageing population, personalized treatment methods, broader access to treatment, concentration on symptom management, and the implementation of cooperative healthcare models. Emerging trends during this forecast period encompass the investigation into gene therapies, the push for patient enlightenment and autonomy, the integration of AI, the enhancement of treatment accessibility, and the development of long-lasting medications.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10807&type=smp

What factors are expected to fuel Emphysema Treatment market growth in the coming years?

The increase in the number of chronic obstructive pulmonary disease (COPD) cases is predicted to spur the growth of the emphysema treatment market. COPD, a group of conditions that cause airflow obstruction and breathing difficulties, includes emphysema and chronic bronchitis. Emphysema treatments target relieving symptoms, restoring lung function, and slowing down the disease’s progression, hence crucial in mitigating the impact of COPD. For example, as the Australian Institute of Health and Welfare (AIHW) reported in June 2024, it was estimated in 2022 that about 638,000 people or 2.5% of Australia’s population lived with COPD. By 2023, the occurrence of COPD had increased to represent 3.6% of the entire disease burden, contributing to half of the total burden relating to respiratory conditions. In 2022, COPD was the fundamental cause of 7,691 deaths, which represents 29.6 deaths per 100,000 people and accounts for 4.0% of all deaths in the nation. As such, the escalating prevalence of COPD is a driving factor in the expansion of the emphysema treatment market.

What Are The Key Findings From The Segmentation Analysis Of The Emphysema Treatment Market?

The emphysema treatment market covered in this report is segmented –

1) By Treatment: Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments

2) By Distribution Channel: Online Providers, Drug Stores and Retail Pharmacies, Hospital Pharmacies

3) By End-User: Clinics, Surgical Centre, Other End-Users

Subsegments:

1) By Smoking Cessation: Nicotine Replacement Therapy (NRT), Prescription Medications, Behavioral Therapy Programs

2) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics

3) By Steroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Combination Inhalers

4) By Leukotriene Modifiers: Montelukast, Zafirlukast

5) By Supplemental Oxygen: Portable Oxygen Concentrators, Continuous Flow Oxygen Systems, Pulse Dose Oxygen Systems

6) By Antibiotics: Macrolides, Fluoroquinolones, Tetracyclines

7) By Gene Therapy: Gene Replacement Therapy, Antisense Oligonucleotides

8) By Surgery Transplant: Lung Volume Reduction Surgery (LVRS), Lung Transplantation

9) By Other Treatments: Pulmonary Rehabilitation Programs, Nutritional Support, Palliative Care

Which Trends Are Expected To Shape The Future Of The Emphysema Treatment Market?

Foremost corporations in the emphysema market are spearheading the development of minimally invasive procedures for patients suffering from emphysema to establish their dominance in the industry. More specifically, minimally invasive procedures allude to medical treatments or surgical methods that cause the least disturbance to the body’s usual functions. For instance, Adena Health System, a health service company based in the US, introduced the Zephyr Valve surgery in January 2022. This less invasive operation offers an alternative to traditional lung volume reduction surgery for patients dealing with lung hyperinflation, a widespread issue in both emphysema and COPD. This novel method includes implanting small, one-directional Zephyr Valves into the lung’s airways through a bronchoscope. These valves enable the expulsion of trapped air, halting any further accumulation, and permit healthier parts of the lung to enlarge, leading to improved respiration.

What Are The Most Active Companies In The Emphysema Treatment Market Today?

Major companies operating in the emphysema treatment market include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Boehringer Ingelheim GmbH, Mylan N.V., Pfizer Inc., Orion Oyj, Verona Pharma PLC, Pulmonx Corporation, Emphasys Medical Inc., Halozyme Therapeutics Inc., Mariposa Health Limited, Uptake Technologies Inc., Respinova Ltd, Gala Therapeutics Inc., Pulmatrix Inc., Broncus Medical Inc., Holaira Inc., PneumRx Inc., Spiration Inc., Aeris Therapeutics Inc., CSA Medical Inc., Olympus Corporation

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/emphysema-treatment-global-market-report

Which Regional Markets Are Attracting The Most Investment In Emphysema Treatment?

North America was the largest region in the emphysema treatment market in 2024. The regions covered in the emphysema treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10807&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Emphysema Treatment Market Grown from 2024 to 2025?

The market for emphysema treatments has witnessed substantial growth over recent years. It is projected to expand from $5.15 billion in 2024 to $5.43 billion in 2025, registering a compound annual growth rate (CAGR) of 5.6%. Factors such as the effect of the smoking epidemic, advancements in pharmaceutical treatments, the introduction of pulmonary rehabilitation programs, enhanced diagnostic instruments, and increased education and awareness have contributed to the growth during the historical period.

What Growth Rate Is Anticipated for the Emphysema Treatment Market in the Coming Years?

The market for emphysema treatment is anticipated to witness robust expansion in the upcoming years. It is projected to reach “$7.4 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.0%. The growth during the forecast period may be contributed to factors such as trends in the aging population, personalized treatment strategies, broadened therapy availability, emphasis on symptom control, and cooperative health care models. The period under forecast is predicted to see major trends like gene therapy exploration, patient education and empowerment, AI integration, enhanced access to treatment, and development of long-acting medications.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10807&type=smp

Who Are the Leading Companies in the Emphysema Treatment Market?

Major companies operating in the emphysema treatment market include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Boehringer Ingelheim GmbH, Mylan N.V., Pfizer Inc., Orion Oyj, Verona Pharma PLC, Pulmonx Corporation, Emphasys Medical Inc., Halozyme Therapeutics Inc., Mariposa Health Limited, Uptake Technologies Inc., Respinova Ltd, Gala Therapeutics Inc., Pulmatrix Inc., Broncus Medical Inc., Holaira Inc., PneumRx Inc., Spiration Inc., Aeris Therapeutics Inc., CSA Medical Inc., Olympus Corporation

What Are the Key Drivers of the Emphysema Treatment Market?

The growth of the emphysema treatment market is expected to be driven by the escalating incidence of chronic obstructive pulmonary disease (COPD). COPD is a collection of disorders leading to obstructions in the airway, resulting in difficulty in breathing, including conditions like emphysema and chronic bronchitis. The use of emphysema therapies is crucial in slowing down the progression of Chronic Obstructive Pulmonary Disease (COPD), as these treatments primarily aim to alleviate symptoms, restore lung functionality, and delay the disease’s progression. As per reports from the Australian Institute of Health and Welfare (AIHW), an Australian agency, it was estimated that approximately 638,000 people, or 2.5% of Australia’s population, had COPD in 2022. By 2023, the disease accounted for 3.6% of the total disease burden, constituting 50% of the complete burden related to respiratory ailments. Moreover, in 2022, COPD was the fundamental cause of 7,691 deaths, amounting to 29.6 deaths per 100,000 individuals and forming 4.0% of all deaths in the country. As a result, the escalating prevalence of COPD positively impacts the emphysema treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10807&type=smp

What Are the Key Market Segments in the Emphysema Treatment Industry?

The emphysema treatment market covered in this report is segmented –

1) By Treatment: Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments

2) By Distribution Channel: Online Providers, Drug Stores and Retail Pharmacies, Hospital Pharmacies

3) By End-User: Clinics, Surgical Centre, Other End-Users

Subsegments:

1) By Smoking Cessation: Nicotine Replacement Therapy (NRT), Prescription Medications, Behavioral Therapy Programs

2) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics

3) By Steroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Combination Inhalers

4) By Leukotriene Modifiers: Montelukast, Zafirlukast

5) By Supplemental Oxygen: Portable Oxygen Concentrators, Continuous Flow Oxygen Systems, Pulse Dose Oxygen Systems

6) By Antibiotics: Macrolides, Fluoroquinolones, Tetracyclines

7) By Gene Therapy: Gene Replacement Therapy, Antisense Oligonucleotides

8) By Surgery Transplant: Lung Volume Reduction Surgery (LVRS), Lung Transplantation

9) By Other Treatments: Pulmonary Rehabilitation Programs, Nutritional Support, Palliative Care

What Are the Latest Trends in the Emphysema Treatment Market?

Leading firms in the emphysema market are focusing on the development of minimally invasive procedures to enhance their market prominence. These procedures involve medical surgeries carried out with little interruption to the body’s normal structure. An example of this is the Zephyr Valve surgery launched in January 2022 by Adena Health System, a healthcare organization based in the U.S. This minimally invasive technique serves as an alternative to traditional lung volume reduction surgery and targets individuals with lung hyperinflation often associated with emphysema and COPD. The groundbreaking process involves implanting small, one-directional Zephyr Valves into the lung airways using a bronchoscope. These valves aid in removing the trapped air, preventing further build-up, and providing room for healthier lung sections to develop and enhance breathing efficiency.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/emphysema-treatment-global-market-report

What Are the Key Regional Markets in the Emphysema Treatment Industry?

North America was the largest region in the emphysema treatment market in 2024. The regions covered in the emphysema treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10807

This Report Delivers Insight On:

1. How big is the emphysema treatment market, and how is it changing globally?

2. Who are the major companies in the emphysema treatment market, and how are they performing?

3. What are the key opportunities and risks in the emphysema treatment market right now?

4. Which products or customer segments are growing the most in the emphysema treatment market?

5. What factors are helping or slowing down the growth of the emphysema treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the emphysema treatment market grown in recent years?

The market for treating emphysema has witnessed robust growth in the past few years. The value of the market is projected to rise from $5.15 billion in 2024 to $5.43 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.6%. Factors such as the impact of the widespread smoking issue, developments in medical treatment, pulmonary rehabilitation initiatives, the evolution of diagnostic tools, and increased knowledge and education have contributed to this growth during the historic period.

How is the emphysema treatment market size expected to evolve during the forecast period?

The market for emphysema treatment is forecasted to experience robust expansion in the coming years, reaching a size of $7.4 billion by 2029, reflecting a compound annual growth rate (CAGR) of 8.0%. This expected growth during the forecast period is driven by factors such as the aging demographic shift, tailored treatment strategies, widened therapy access, emphasis on symptom control, and integrated healthcare approaches. Key predictive trends include gene therapies exploration, enhancement of patient knowledge and autonomy, the incorporation of artificial intelligence (AI), improved treatment accessibility, and the making of long-acting drugs.

Get your emphysema treatment market report here!

https://www.thebusinessresearchcompany.com/report/emphysema-treatment-global-market-report

Which key drivers are propelling the emphysema treatment market’s growth?

The surge in chronic obstructive pulmonary disease (COPD) instances is predicted to boost the emphysema treatment market’s expansion. Emphysema and chronic bronchitis are among the disorders that cause airflow obstruction and breathing difficulty, collectively referred to as COPD. Emphysema treatments are critical in slowing the progression of COPD due to their focus on symptom management, lung function restoration, and disease progression delay. For instance, the Australian Institute of Health and Welfare (AIHW) published reports in June 2024 that estimated about 638,000 individuals or 2.5% of Australia’s population were living with COPD in 2022. By 2023, COPD had grown to represent 3.6% of the total disease burden, accounting for 50% of the total burden associated with respiratory conditions. Moreover, in 2022, COPD caused 7,691 deaths, translating to 29.6 fatalities per 100,000 people and accounting for 4.0% of all deaths in the country. Hence, the increasing prevalence of COPD cases fuels the emphysema treatment market’s growth.

What are the market segments in the emphysema treatment industry?

The emphysema treatment market covered in this report is segmented –

1) By Treatment: Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments

2) By Distribution Channel: Online Providers, Drug Stores and Retail Pharmacies, Hospital Pharmacies

3) By End-User: Clinics, Surgical Centre, Other End-Users

Subsegments:

1) By Smoking Cessation: Nicotine Replacement Therapy (NRT), Prescription Medications, Behavioral Therapy Programs

2) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics

3) By Steroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Combination Inhalers

4) By Leukotriene Modifiers: Montelukast, Zafirlukast

5) By Supplemental Oxygen: Portable Oxygen Concentrators, Continuous Flow Oxygen Systems, Pulse Dose Oxygen Systems

6) By Antibiotics: Macrolides, Fluoroquinolones, Tetracyclines

7) By Gene Therapy: Gene Replacement Therapy, Antisense Oligonucleotides

8) By Surgery Transplant: Lung Volume Reduction Surgery (LVRS), Lung Transplantation

9) By Other Treatments: Pulmonary Rehabilitation Programs, Nutritional Support, Palliative Care

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10807&type=smp

Which leading companies are shaping the growth of the emphysema treatment market?

Major companies operating in the emphysema treatment market include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Boehringer Ingelheim GmbH, Mylan N.V., Pfizer Inc., Orion Oyj, Verona Pharma PLC, Pulmonx Corporation, Emphasys Medical Inc., Halozyme Therapeutics Inc., Mariposa Health Limited, Uptake Technologies Inc., Respinova Ltd, Gala Therapeutics Inc., Pulmatrix Inc., Broncus Medical Inc., Holaira Inc., PneumRx Inc., Spiration Inc., Aeris Therapeutics Inc., CSA Medical Inc., Olympus Corporation

What key trends are currently impacting the emphysema treatment market’s development?

To maintain their competitive advantage in the emphysema market, major companies are innovating and focusing on minimally invasive procedures for patients. These types of medical interventions or surgical techniques cause minimal disruption to the body’s regular structures. For example, the Zephyr Valve surgery, a minimally invasive procedure, was introduced by Adena Health System, a US-based healthcare firm, in January 2022. This provides an alternative to traditional lung volume reduction surgery for sufferers of lung hyperinflation, which is frequently an issue with emphysema and COPD. This innovative method involves the placement of tiny, one-directional Zephyr Valves in the lung’s airways through a bronchoscope. These valves help in releasing entrapped air, avoid further buildup, and enable healthier sections of the lung to expand, thus enhancing breathing.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10807

Which geographic areas are influencing the growth of the emphysema treatment market?

North America was the largest region in the emphysema treatment market in 2024. The regions covered in the emphysema treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Autoimmune Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Infertility Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/infertility-treatment-global-market-report

Point Of Entry Water Treatment Systems Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/point-of-entry-water-treatment-systems-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Growth Potential of the Emphysema Treatment Market, and How Will It Perform by 2034?

The market for emphysema treatment has seen significant expansion in the past few years. The size of the market is set to increase from $5.15 billion in 2024 to $5.43 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. The considerable growth witnessed in the past is due to factors such as the impact of the smoking epidemic, advancements in medicine, the implementation of pulmonary rehabilitation programs, the development of better diagnostic tools, and increased awareness and education.

Looking ahead, the market size of emphysema treatments is set to experience significant growth in the upcoming years, projecting a rise to “$7.4 billion by 2029 with a compound annual growth rate (CAGR) of 8.0%. This expected surge during the forecast period is largely due to factors such as the increase in the aging population, personalization of treatment methods, better access to treatment options, attention to symptom management and the establishment of collaborative healthcare models. Key trends to look out for during this period range from the development of gene therapies and patient enlightenment and involvement to artificial intelligence (AI) incorporation, improved treatment accessibility, and the creation of long-acting medications.

What Market Dynamics Are Playing a Key Role in Accelerating the Growth of the emphysema treatment Market?

The escalating incidence of Chronic Obstructive Pulmonary Disease (COPD) is anticipated to fuel the expansion of the emphysema treatment market. COPD encompasses conditions that result in airflow obstruction and trouble breathing, including emphysema and chronic bronchitis. Treatments for emphysema are crucial for mitigating COPD’s progression as they target symptoms, heal lung function, and slow the progression of the disease. For example, the Australian Institute of Health and Welfare (AIHW) reported in June 2024 that around 638,000 individuals, or 2.5% of the Australian population, were living with COPD in 2022. By 2023, COPD’s prevalence had increased to represent 3.6% of the total disease burden, accounting for 50% of the overall respiratory condition burden. Additionally, in 2022, COPD was the reason behind 7,691 deaths, translating to 29.6 deaths per 100,000 people, and making up 4.0% of all mortalities in the country. Hence, the growing predominance of COPD cases stimulates the emphysema treatment market.

Explore Comprehensive Insights Into The Global Emphysema Treatment Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10807&type=smp

Who Are the Major Companies Shaping the Competitive Landscape of the Emphysema Treatment Market?

Major companies operating in the emphysema treatment market include:

• AstraZeneca PLC_x000D_

• Teva Pharmaceutical Industries Ltd._x000D_

• Novartis AG_x000D_

• GlaxoSmithKline PLC_x000D_

• Hikma Pharmaceuticals PLC_x000D_

What Are the Key Emerging Trends in the Emphysema Treatment Market for the Next Decade?

Leading businesses in the emphysema market are creating minimally invasive processes to gain a strategic advantage. These are medical interventions or surgical methods which cause minimal damage to normal bodily structures. For example, in January 2022, Adena Health System, a healthcare company in the US, rolled out the Zephyr Valve surgery. This new minimally invasive technique presents an option aside from the traditional lung volume reduction surgery for those dealing with lung hyperinflation, a recurring problem in emphysema and COPD. This ground-breaking method involves the insertion of tiny, one-directional Zephyr Valves into the lung airways using a bronchoscope. These valves assist in releasing trapped air, stopping further build-up, and enabling healthier sections of the lung to enlarge, resulting in improved breathing.

Secure Your Global Emphysema Treatment Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/emphysema-treatment-global-market-report

Which Key Segments Stand Out in Understanding the Composition of the Emphysema Treatment Market?

The emphysema treatment market covered in this report is segmented –

1) By Treatment: Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments

2) By Distribution Channel: Online Providers, Drug Stores and Retail Pharmacies, Hospital Pharmacies

3) By End-User: Clinics, Surgical Centre, Other End-Users

Subsegments:

1) By Smoking Cessation: Nicotine Replacement Therapy (NRT), Prescription Medications, Behavioral Therapy Programs

2) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics

3) By Steroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Combination Inhalers

4) By Leukotriene Modifiers: Montelukast, Zafirlukast

5) By Supplemental Oxygen: Portable Oxygen Concentrators, Continuous Flow Oxygen Systems, Pulse Dose Oxygen Systems

6) By Antibiotics: Macrolides, Fluoroquinolones, Tetracyclines

7) By Gene Therapy: Gene Replacement Therapy, Antisense Oligonucleotides

8) By Surgery Transplant: Lung Volume Reduction Surgery (LVRS), Lung Transplantation

9) By Other Treatments: Pulmonary Rehabilitation Programs, Nutritional Support, Palliative Care

Which Regions Are Making a Mark in the Emphysema Treatment Market Growth?

North America was the largest region in the emphysema treatment market in 2024. The regions covered in the emphysema treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Does the Definition of the Emphysema Treatment Market Include?

Emphysema treatment is a medication for chronic obstructive pulmonary disease (COPD) that causes damage to the lungs’ air sacs, making breathing difficult. Emphysema treatments are available to control symptoms and decrease disease development of emphysema.

Browse Through More Similar Reports By The Business Research Company:

Autoimmune Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Infertility Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/infertility-treatment-global-market-report

Point Of Entry Water Treatment Systems Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/point-of-entry-water-treatment-systems-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: